Company intelligence / Profile preview

NeoStem

New York City, New York, United Statesneostem.org ↗

Ownership: Private
Employees: ~156
Development stage: Other

Overview

NeoStem developed a diverse pipeline of autologous and allogeneic cell therapies. Its lead program, Melapuldencel-T, showed significant improvement in two-year overall survival for advanced melanoma patients in Phase 2 trials and was approved to enter Phase 3 with Fast Track and Orphan Drug designations. AMR‑001 entered Phase 2 trials for preserving heart function after myocardial infarction. The company also advanced early-stage programs targeting autoimmune diseases and regenerative medicine applications.

Therapeutic areas: ImmunologyCardiovascularOncologyOther
Modalities: Stem cell therapyCell therapyDendritic cell therapyT-cell therapy
Industry: Biotech

Partnerships

Becton Dickinson & Company

Beyond the preview

Go deeper on NeoStem.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeoStem.

Explore the full profile